Keros Therapeutics
在场
高管
查看带有其 16 名主要高管的组织结构图
Keros Therapeutics 搜索最多的简介
- Jasbir Seehra, Chief Executive Officer and Chairman of the Board
- Nima Farzan, Director
- Mary Ann Gray, Director
高管在Keros Therapeutics变化
- Yung Chyung已作为Chief Medical Officer加入公司 (新闻发布的2024十月18号).
- Jasbir Seehra 曾任 Chief Executive Officer and Director, 将于 20247月1 升职为 Chief Executive Officer and Chairman of the Board (新闻发布的2024六月18号).
- Jean-Jacques Bienaimé 曾任 Director, 将于 20247月1 升职为 Lead Independent Director (新闻发布的2024六月18号).
创建提醒
跟踪 Keros Therapeutics 的高管变动
生物技术
Keros Therapeutics 拥有 2,335 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Visus Therapeutics and Tenpoint Therapeutics have merged (公布2024十二月27号)..
- Deerfield has announced the acquisition of Singular Genomics (公布2024十二月24号).
- Aadi Bioscience 刚刚宣布为 100 筹款数百万美元。 (公布2024十二月20号).
生物技术 行业的其他推荐联系人
消息
Keros Therapeutics 的最新新闻稿
- Keros Therapeutics appoints Keith Regnante as Chief Financial Officer — Keros Therapeutics (Copy)
- Keros Therapeutics Receives $23 million Series B Funding for Development of Therapies to Treat Debilitating Neuromuscular Diseases — Keros Therapeutics (Copy)
- Keros Therapeutics Closes $56 Million Series C Financing to Advance its Programs in Hematologic and Musculoskeletal Disorders — Keros Therapeutics (Copy)
- Keros Therapeutics Receives $23 million Series B Funding for Development of Therapies to Treat Debilitating Neuromuscular Diseases — Keros Therapeutics
- Keros Therapeutics appoints Keith Regnante as Chief Financial Officer — Keros Therapeutics
- Keros Therapeutics Closes $56 Million Series C Financing to Advance its Programs in Hematologic and Musculoskeletal Disorders — Keros Therapeutics
- View more press releases Close
通过电子邮件
